Coherus Biosciences | CHRS - Current Assets

Stock Price
1.99
Daily Change
0.24 13.43%
Monthly
16.08%
Yearly
94.61%
Q2 Forecast
1.71

Coherus Biosciences reported $206.71M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Fujifilm JPY 1.72T 120.76B Dec/2025
Gilead Sciences USD 18.64B 1.25B Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Teva Pharmaceutical Industries USD 13.71B 236M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026
Zoetis USD 6.47B 294M Mar/2026